Selfotel
Selfotel
Chemical compound
Selfotel (CGS-19755) is a drug which acts as a competitive NMDA antagonist, directly competing with glutamate for binding to the receptor.[1] Initial studies showed it to have anticonvulsant, anxiolytic, analgesic and neuroprotective effects,[2][3] and it was originally researched for the treatment of stroke,[4] but subsequent animal and human studies showed phencyclidine-like effects,[5][6][7][8] as well as limited efficacy and evidence for possible neurotoxicity under some conditions,[9][10][11] and so clinical development was ultimately discontinued.[12][13]
Quick Facts Clinical data, Other names ...
Clinical data | |
---|---|
Other names | Selfotel |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C7H14NO5P |
Molar mass | 223.165 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
Close
- France CP, Winger GD, Woods JH (September 1990). "Analgesic, anesthetic, and respiratory effects of the competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 in rhesus monkeys". Brain Research. 526 (2): 355–8. doi:10.1016/0006-8993(90)91247-e. hdl:2027.42/28393. PMID 2257491.
- Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, et al. (April 1995). "Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial". Stroke. 26 (4): 602–5. doi:10.1161/01.str.26.4.602. PMID 7709405.
- Lu Y, France CP, Woods JH (November 1992). "Tolerance to the cataleptic effect of the N-methyl-D-aspartate (NMDA) receptor antagonists in pigeons: cross-tolerance between PCP-like compounds and competitive NMDA antagonists". The Journal of Pharmacology and Experimental Therapeutics. 263 (2): 499–504. PMID 1432686.
- Baron SP, Woods JH (March 1995). "Competitive and uncompetitive N-methyl-D-aspartate antagonist discriminations in pigeons: CGS 19755 and phencyclidine". Psychopharmacology. 118 (1): 42–51. doi:10.1007/bf02245248. hdl:2027.42/46346. PMID 7597121.
- Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF (November 1999). "Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators". Journal of Neurosurgery. 91 (5): 737–43. doi:10.3171/jns.1999.91.5.0737. PMID 10541229.
- Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J (February 2000). "Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist". Stroke. 31 (2): 347–54. doi:10.1161/01.str.31.2.347. PMID 10657404.
- Farin A, Marshall LF (2004). "Lessons from epidemiologic studies in clinical trials of traumatic brain injury". Mechanisms of Secondary Brain Damage from Trauma and Ischemia. Vol. 89. pp. 101–7. doi:10.1007/978-3-7091-0603-7_14. ISBN 978-3-7091-7206-3. PMID 15335108.
{{cite book}}
:|journal=
ignored (help)
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |